1606 Corp Stock Price, News & Analysis

1606 Corp. (OTC Pink:CBDW) has expressed strong support for Adnexus Biotechnologies' new Neural Temporal Fingerprinting technology, which combines AI-driven analysis of EEG and ECG signals for health monitoring. The technology focuses on neurological prediction for conditions like Alzheimer's and PTSD, and cardiovascular risk assessment for heart-related conditions.

While a previous Letter of Intent for strategic investment between the companies terminated on November 28, 2024, both parties are continuing efforts to close the transaction. The partnership aims to advance AI-powered healthcare solutions and position both companies for growth in the personalized medicine market.

1606 Corp. (OTC PINK:CBDW) reports progress in Q3 2024, focusing on AI chatbot market expansion and strategic partnerships. The company has filed its 10-Q for Q3 2024, maintaining current SEC filing status. Key developments include signing a Letter of Intent with Adnexus Biotechnologies for potential strategic investment in AI and biotechnology solutions. The company has created two chatbots (available at cbdw.ai) and plans to expand into e-commerce, finance, healthcare, and telecommunications sectors. Future focus includes closing the Adnexus investment, launching additional AI chatbot solutions, and expanding market presence.

1606 Corp (OTC PINK:CBDW) announces that its investment target Adnexus Biotechnologies has completed a merger agreement to acquire Sanctum Therapeutics' core technology assets for HIV and SARS-CoV-2 treatments. The merger combines Adnexus's AI-driven drug discovery platform with Sanctum's long-acting HIV capsid inhibitor and Adnexus's anti-HIV monoclonal antibodies. 1606 Corp has executed a Letter of Intent for a 5% strategic investment in Adnexus, with the LOI terminating on November 27, 2024.

1606 Corp. (OTC PINK:CBDW), a leader in AI chatbot solutions, is hosting an exclusive live investor webinar and Q&A session on October 10, 2024, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature CEO Austen Lambrecht discussing the company's innovative product portfolio and near-term expansion plans. Investors can register for free at the provided link and submit questions in advance to CBDW@redchip.com or during the live event.

1606 Corp. (OTC PINK:CBDW) has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a company specializing in AI-driven drug discovery and infectious disease research. This potential investment aligns with 1606 Corp.'s goal to expand its AI capabilities and impact healthcare and biotechnology sectors.

Adnexus operates an advanced AI platform called SUTRA, which identifies specific sites and biomarkers for infectious and neurological diseases. The platform has successfully produced human monoclonal antibodies unaffected by virus mutations, utilizing data from 19 viruses, 8 million molecules, and human microbiome samples.

The collaboration aims to enhance technological capabilities and drive breakthroughs in drug discovery and infectious disease treatment. The transaction is subject to due diligence and certain conditions outlined in the LOI.

1606 Corp. (OTC Pink:CBDW), an AI technology developer, has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a leading AI biotech company. This potential investment aims to expand 1606 Corp.'s technological capabilities in AI-driven healthcare and biotech solutions. Adnexus is known for its groundbreaking work in AI-powered early drug discovery and infectious disease research, including HIV and SARS-COV-2 treatments.

The partnership would combine 1606 Corp.'s strengths in conversational AI and chatbot technology with Adnexus's innovative research efforts. Adnexus's unique methodology uses human "immune-B cells" from recovered individuals to create fully human monoclonal antibodies. The transaction is subject to due diligence and certain conditions. Both companies anticipate significant value creation for shareholders and technological advancement in their respective fields.

1606 Corp (OTC PINK:CBDW), a leader in AI chatbots, has reported significant updates for Q2 2024. Under new CEO Austen Lambrecht, the company has made advancements in AI technology and expanded its global footprint. Key highlights include:

1. Launch of an expanded AI email marketing campaign for ChatCBD and IR Chat.
2. Filing of the Quarterly Report on Form 10-Q for Q2 2024, maintaining current status with all filings.
3. Ongoing discussions about potential mergers and acquisitions in the AI sector.
4. Invitation to present at the NIBA Show in Florida on September 4-5, 2024, offering an opportunity to showcase AI innovations and connect with institutional investors.

The company is focused on leveraging its technological advancements and AI marketing expansion to drive future growth in the AI chatbot industry.

1606 Corp. (OTC PINK:CBDW), a leader in AI chatbot solutions, has appointed Austen Lambrecht as its new CEO and Chairman of the Board, effective May 31, 2024. Lambrecht, previously Vice President of 1606, brings experience from public companies and AI chatbots. Since his appointment, CBDW's stock price has more than doubled and trading volume has more than tripled.

Lambrecht's career includes roles at SinglePoint Inc and significant achievements at 1606, such as acquiring a stock symbol, maintaining OTC Markets compliance, and leading the company's AI technology transition. Under his leadership, CBDW developed AI Chatbots for CBD and Investor Relations sectors.

An upcoming webinar hosted by RedChip Companies will feature Lambrecht discussing the company's product portfolio and expansion plans.

1606 Corp. (OTC PINK:CBDW), a leader in AI chatbot solutions, will host an exclusive live investor webinar and Q&A session on June 11, 2024, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature the new CEO, Austen Lambrecht, who will discuss the company's innovative product portfolio and expansion plans. Investors can register for the free webinar on the provided Zoom link and submit questions before or during the event. Visit cbdw.ai to try the company's AI bot tailored for the public company and CBD market.